Zonisamide: a new antiepileptic drug

Area of Science:

• Pharmacology
• Neurology
• Clinical Medicine

Background:

• Zonisamide (ZNS) is an antiepileptic medication with established use in Japan.
• Previous attempts to market ZNS in the US were hindered by nephrolithiasis reports.
• Successful Japanese marketing has prompted renewed interest in US approval.

Purpose of the Study:

• To review the efficacy and safety of Zonisamide (ZNS) based on Japanese clinical experience.
• To provide an overview of ZNS's potential therapeutic applications and mechanisms of action.
• To inform the potential reintroduction of ZNS into the United States market.

Main Methods:

• Review of Japanese clinical data on Zonisamide (ZNS) efficacy and adverse events.
• Analysis of ZNS's proposed mechanisms of action, including channel blocking and antioxidant properties.
• Summary of recommended dosing regimens and therapeutic plasma concentrations for ZNS.

Main Results:

• ZNS demonstrates broad-spectrum efficacy against various seizure types, including infantile spasms and myoclonic seizures.
• Reported neuroprotective and antimanic effects suggest broader therapeutic potential.
• Adverse events like drowsiness and GI issues are associated with plasma concentrations exceeding 30 mg/L, with nephrolithiasis being a notable concern.

Conclusions:

• Zonisamide (ZNS) offers a wide range of antiepileptic efficacy, supported by Japanese clinical data.
• Understanding ZNS's mechanism of action and dose-dependent adverse events is crucial for safe and effective use.
• Further evaluation is warranted for ZNS's potential US market entry, considering both benefits and risks.